Sirolimus- versus paclitaxel-eluting stent implantation for unprotected left main coronary artery stenosis

Cardiology

Volumn 104, Issue 4, 2005, Pages 181-185

  Sang, Hak Lee ^a   Ko, Young Guk ^b   Jang, Yangsoo ^b   Hyuck, Moon Kwon ^c   Lee, Seung Hwan ^g   Yoon, Jung Han ^g,i   Si, Hoon Park ^d   Byung, Ok Kim ^e   Dong, Woon Jeon ^h   Joo, Young Yang ^h   Ryu, Seung Ki ^f  

^a Kangnam Sacred Heart Hospital   (South Korea)

^b Yonsei University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Mokdong Hospital   (South Korea)

^e Inje University College of Medicine   (South Korea)

^f Eulji General Hospital   (South Korea)

^g Wonju Severance Christian Hospital   (South Korea)

^h National Health Insurance Corporation   (South Korea)

ⁱ Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

Coronary stenosis; Paclitaxel; Sirolimus; Stents

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ADULT; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; IMPLANTATION; LEFT CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTENOSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD VESSEL PROSTHESIS IMPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PACLITAXEL; SIROLIMUS; STENTS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 26044473604     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088106     Document Type: Article

References (14)

1. Park SJ, Park SW, Hong MK, Cheong SS, Lee CW, Kim JJ, Mintz GS, Leon MB: Stenting of unprotected left main coronary artery stenoses: immediate and late outcomes. J Am Coll Cardiol 1998;31:37-42.
2. Silvestri M, Baragan P, Sainsous J, Bayet G, Simeoni JB, Roquebert PO, Macaluso G, Bouvier JL, Comet B: Unprotected left main coronary artery stenting: immediate and medium-term outcomes of 140 elective procedures. J Am Coll Cardiol 2000;35:1543-1550.
3. Arampatzis CA, Lemos PA, Tanabe K, Hoye A, Degertekin M, Saia F, Lee CH, Ruiter A, McFadden E, Sianos G, Smits PC, van der Giessen WJ, de Feijter P, van Domburg R, Serruys PW: Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease. Am J Cardiol 2003;92:327-329.
4. Arampatzis CA, Lemos PA, Hoye A, Saia F, Tanabe K, van der Giessen WJ, Smits PC, McFadden E, de Feyter P, Serruys PW: Elective sirolimus-eluting stent implantation for left main coronary artery disease: six-month angiographic follow-up and 1 -year clinical outcome. Catheter Cardiovasc Interv 2004;62:292-296.
5. De Lezo JS, Medina A, Pan M, Delgado A, Segura J, Pavlovic K, Melian F, Romero M, Burgos L, Hernandez E, Urena I, Herrador J: Rapamycin-eluting stents for the treatment of unprotected left main coronary disease. Am Heart J 2004;148:481-485.
6. Park SJ, Kim YH, Lee BK, Lee SW, Lee CW, Hong MK, Kim JJ, Mintz GS, Park SW: Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis. J Am Coll Cardiol 2005;45:351-356.
7. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985;312:932-936.
8. Hill RA, Dundar Y, Bakhai A, Dickson R, Walley T: Drug-eluting stents: an early systematic review to inform policy. Eur Heart J 2004;25:902-919.
9. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ: A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents. Lancet 2004; 364: 583-591.
10. Valgimigli M, van Mieghem CA, Ong AT, Aok J, Granillo GA, McFadden EP, Kappetein AP, de Feyter PJ, Smits PC, Regar E, Van der Giessen WJ, Sianos G, de Jaegere P, Van Domburg RT, Serruys PW: Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insight from the Rapamycin-Eluting and Taxus Stent Evaluated at Rotterdam Cardiology registries (RESEARCH and T-SEARCH). Circulation 2005;111:1383-1389.
11. Ikovou I, Stankovic G, Montorfano M, Airoldi F, Chieffo A, Sangiorgi GM, Carlino M, Corvaja N, Iassen M, Rogacka R, Vitrella G, Colombo A: Is overdilatation of 3.0 mm sirolimus-eluting stent associated with a higher restenosis rate? Catheter Cardiovasc Interv 2005;64:129-133.
12. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GS: A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-1545.
13. Goy JJ, Stauffer JC, Siegenthaler M, Benoit A, Seydoux C: A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology. J Am Coll Cardiol 2005;45:308-311.
14. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schuhlen H, Schmitt C, Dirschinger J, Schomig A, for ISAR-DESIRE Study Investigators: Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005;293:165-171.